Real-world Effect of Monoclonal Antibody Treatment in COVID-19 Patients in a Diverse Population in the United States.
Kaitlin Rainwater-LovettJohn T ReddMiles A StewartNatalia Elías CallesTyler CluffMike FangMark J PanaggioAnastasia S LambrouJonathan K ThornhillChristopher BradburneSamuel ImbrialeJeffrey D FreemanMichael AndersonRobert P KadlecPublished in: Open forum infectious diseases (2021)
In this diverse, real-world COVID-19 patient population, mAb treatment significantly decreased the risk of subsequent ED visit or hospitalization. Broader treatment with mAbs, including in disadvantaged patient populations, can decrease the burden on hospitals and should be facilitated in all populations in the United States to ensure health equity.